Ipsen’s ultra-rare bone disease drug flops in Phase II trial
Ipsen’s failure comes shortly after Regeneron’s FOP study met its endpoints, sparking an FDA approval submission.
Therapy Area
England sees increase in influenza hospitalisations
Precision medicine approaches needed in oncology to match evolving SoC
Gilead’s HIV ART combo deemed non-inferior in second Phase III trial
Sanofi shares fall 6% after double setback for MS drug tolebrutinib
Lilly’s triple G agonist boasts 28.7% weight loss in Phase III trial
ASH 2025: J&J’s Tecvayli + Darzalex set to redefine early relapsed MM
GRI Bio’s tazarotene achieves Phase IIa IPF success
